Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

144.57 +7.61 (+5.56%)
Streaming Delayed Price Updated: 10:44 AM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Why Are Guardant Health (GH) Shares Soaring Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 6.1% in the morning session after its stock hit a 52-week high following rece... 
Via StockStory
News headline image
3 Russell 2000 Stocks We Approach with Caution
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
Topics Energy
Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick ↗
Via Chartmill
News headline image
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Grail Could Be the Sleeper Stock Everyone's About to Notice ↗
Grail is on a quest to win in a $50 billion market. 
Via The Motley Fool
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue ↗
Via Chartmill
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
Topics Electric Vehicles
News headline image
3 Reasons GH is Risky and 1 Stock to Buy Instead
Over the past six months, Guardant Health has been a great trade, beating the S&P 500 by 11.7%. Its stock price has climbed to $129.08, representing a health... 
Via StockStory
Topics Bankruptcy Stocks Supply Chain
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industr... 
Via StockStory
News headline image
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
News headline image
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Growth Stocks We’re Skeptical Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Down Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 4.1% in the afternoon session after Co-CEO AmirAli Talasaz sold 50,000 shares o... 
Via StockStory
News headline image
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
Guardant Health delivered a strong start to 2026, outperforming Wall Street’s revenue expectations in Q1 as robust demand across its core oncology, biopharma... 
Via StockStory
Topics Earnings
News headline image
Guardant Health (GH) Q1 2026 Earnings Transcript ↗
Guardant Health (GH) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2026, with sales up 48.3% year on year to $301.7 million. The ... 
Via StockStory
News headline image
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 48.3% year on year to $... 
Via StockStory
News headline image
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Earnings: What To Look For From GH
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after the bell. Here’s what you need to know. Guardant Health beat an... 
Via StockStory
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.